PANADOL

500 MG · film-coated tablet · box of 20

Historical reference: this presentation is not marketed, withdrawn or suspended according to the source. Its listed price does not establish availability.

Reference dated : 2026-10-01. Confirm price and availability with a pharmacist.

Public price

13,50 MAD

Laboratory

GSK

Composition and presentation

PANADOL — PARACETAMOL. Listed presentation: 500 MG · COMPRIME PELLICULE · BOITE DE 20.

Full clinical reference

Additional sections are available in French. Read the original document; the information concerns the French reference product.

Uses

Symptomatic treatment of mild to moderate pain and/or fever.

Adult and child from 27 kg (approximately 8 years).

Pregnancy and breastfeeding

Pregnancy

A vast amount of data concerning pregnant women demonstrate the absence of any malformation or any fetal/neonatal toxicity. Epidemiological studies dedicated to the neurodevelopment of children exposed to paracetamol in utero produce inconclusive results. If this proves necessary from a clinical point of view, paracetamol can be used during pregnancy; however, it should be used at the lowest effective dose, for the shortest possible duration and at the lowest possible frequency.

Breastfeeding

After administration, paracetamol is eliminated in small amounts in breast milk. At therapeutic doses, the administration of this medicine is possible during breastfeeding.

Fertility

Due to the potential mechanism of action on cyclo-oxygenases and prostaglandin synthesis, paracetamol could alter fertility in women, through an effect on ovulation reversible upon discontinuation of treatment.

Effects on male fertility have been observed in an animal study. The relevance of these effects in humans is unknown.

Driving

Paracetamol has no effect or a negligible effect on the ability to drive vehicles and use machines.

Adverse effects

Adverse effects are classified by system-organ class. Their frequencies are defined as follows:

· Very frequent ( ≥ 1/10)

· Frequent ( ≥ 1/100 to < 1/10)

· Uncommon ( ≥ 1/1000 to < 1/100)

· Rare ( ≥ 1/10 000 to < 1/1000)

· Very rare (< 1/10 000)

· Frequency unknown (cannot be estimated on the basis of available data)

System organ class	Rare ( ≥ 1/10 000 to < 1/1 000)	· Very rare (< 1/10 000)	Frequency unknown
Hematological and lymphatic system disorders		Thrombopenia, Leukopenia, Neutropenia
Immune system disorders	Hypersensitivity reactions 1		Anaphylactic reaction (including hypotension) 1, Anaphylactic shock 1, Angioedema (Quincke's edema) 1
Respiratory, thoracic and mediastinal disorders			Bronchospasm 3 .
Metabolism and nutrition disorders			High anion gap metabolic acidosis 4
Gastrointestinal disorders	Diarrhea, Abdominal pain.
Hepatobiliary disorders			Increase in liver enzymes
Skin and subcutaneous tissue disorders	Erythema 1, Urticaria 1, Skin rash 1, Purpura 2	Serious skin reactions 1	Fixed pigment erythema
1 Their occurrence requires the immediate and permanent discontinuation of this medicinal product and related medicinal products. 2 The occurrence of this effect requires the immediate discontinuation of this medicinal product. The medicinal product may be reintroduced only on medical advice. 3 Cases of bronchospasm have been identified with paracetamol, mostly in asthmatic patients sensitive to aspirin or other non-steroidal anti-inflammatory drugs 4 Cases of high anion gap metabolic acidosis due to pyroglutamic acidosis have been reported in patients presenting with risk factors and taking paracetamol (see section 4.4). Pyroglutamic acidosis may occur in these patients due to low glutathione levels.

Reporting of suspected adverse effects

Reporting suspected adverse effects after authorisation of the medicinal product is important. It allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals report any suspected adverse effect via the national reporting system: French National Agency for Medicines and Health Products Safety (ANSM) and the network of Regional Pharmacovigilance Centres - Website: https://signalement.social-sante.gouv.fr/ .

Read the French reference

Hospital price

8,50 MAD

Commercial status

Non Commercialisé

Therapeutic class

ANTALGIQUES-ANALGESIQUES-ANTIPYRETIQUES-ANTI-INFLAMMATOIRES-ANTISPASMODIQUES

References and update dates

AMMPS — catalogue marocain officiel · 2026-10-01

Product and price reference

This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.

Price history

Reference price recorded since 2026-10-01: 13,50 MAD

Reference price recorded since 2026-06-01: 13,50 MAD

Other strengths and forms

Routes and instructions may differ.